NASDAQ · RANI

Rani Therapeutics Holdings, Inc.

$0.85 -$0.04 (-4.39%) 1D After hours
Session Pulse After hours 1 mentions on Tue No new SEC filings since Mon close its sector ranked 6/11 this week Full pulse →

Key Metrics

$100.03M
Market cap
P/E · TTM
$3.17M
Revenue · TTM
−$29.44M
Net income
EPS · TTM $-0.88
Dividend yield
Free cash flow −$17.11M
Beta · 1Y 2.69
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 22
    The stock moved +29.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 22
  • Jul 21
    An insider transaction hit the record.

    Form 4s are events, not verdicts — officers, directors, and 10% owners reporting their own trades. The forms post hours before the media writes them up.

    RECEIPT: SEC FORM 4, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 13
    From its Feb 26 high, the share price fell 54%.

    Peak close $1.38 on Feb 26; trough close $0.63 on Jul 13. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -54%
  • Mar 27
    The stock moved -24.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 27

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$100.03M
Enterprise value
Shares outstanding112.4M
52-wk range$0.44 – $3.87
Avg volume · 20D1.4M
Net cash
Book value / share$0.85
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Rani Therapeutics Holdings, Inc.
IPO dateJul 30, 2021
Employees69

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S31.56
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -1,093.0%
Net -929.1%
FCF -540.0%
ROE / ROIC -193.7% · —

Financial Health

Current ratio3.40
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$33.24M

Cash Flow · TTM

Operating CF −$17.06M
Capex −$52.00K
Free cash flow −$17.11M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

-1.5
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings